Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab In Patients With Oral Lichen Planus
DRKS00024971Phase 2Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of guselkumab in oral lichen planus (OLP), sponsored by Philipps-Universität Marburg. Started Oct 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on DRKS00024971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024971.